Table 1.
Patient's parameter | Non‐hypermethylated (n = 50) | Hypermethylated (n = 49) | P value |
---|---|---|---|
Sex (male/female) | 28/22 | 28/21 | 1.000 |
Age (years) | 56 (14–85) | 62 (20–86) | 0.122 |
WBC (×109/l) | 2.9 (1.3–19.5) | 2.7 (0.9–82.4) | 0.934 |
HB (g/l) | 64 (26–128) | 65 (38–118) | 0.869 |
PLT (×109/l) | 61.5 (3–1176) | 47 (0–754) | 0.746 |
BM blasts (%) | 2.0 (0.0–16.5) | 6.0 (0.0–27.0) | 0.069 |
Cytogenetic classification | |||
Good | 36 (72%) | 34 (69%) | 0.677 |
Intermediate | 9 (18%) | 7 (14%) | |
Poor | 2 (4%) | 5 (10%) | |
No data | 3 (6%) | 3 (6%) | |
IPSS | |||
Low | 7 (14%) | 2 (4%) | 0.008 |
Int‐1 | 32 (64%) | 26 (53%) | |
Int‐2 | 8 (16%) | 9 (18%) | |
High | 0 (0%) | 9 (18%) | |
No data | 3 (6%) | 3 (6%) | |
Gene mutations | |||
CEBPA (+/−) | 2/47 | 0/47 | 0.495 |
IDH1/2 (+/−) | 3/46 | 1/46 | 0.617 |
DNMT3A (+/−) | 0/49 | 3/44 | 0.113 |
U2AF1 (+/−) | 1/48 | 6/41 | 0.057 |
SF3B1 (+/−) | 3/46 | 3/44 | 1.000 |
Median (range); WBC: white blood cells; HB: haemoglobin; PLT: platelet count; BM: bone marrow; IPSS: International Prognostic Scoring System; WHO: World Health Organization; RA: refractory anaemia; RARS: RA with ringed sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCMD‐RS: RCMD with ringed sideroblasts; RAEB: RA with excess of blasts.